Michael Gold to Primary Prevention
This is a "connection" page, showing publications Michael Gold has written about Primary Prevention.
Connection Strength
2.481
-
Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021 01 05; 143(1):7-17.
Score: 0.657
-
Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm. 2019 11; 16(11):1636-1644.
Score: 0.594
-
HRS expands global reach to advance prevention and treatment strategies for arrhythmias. Heart Rhythm. 2016 12; 13(12):2271.
Score: 0.502
-
1-Year Prospective Evaluation of Clinical Outcomes and Shocks: The?Subcutaneous?ICD?Post?Approval Study. JACC Clin Electrophysiol. 2020 11; 6(12):1537-1550.
Score: 0.163
-
Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008631.
Score: 0.161
-
Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1236-44; discussion 1244-5.
Score: 0.102
-
Economic implications and cost-effectiveness of implantable cardioverter defibrillator and cardiac resynchronization therapy. Heart Fail Clin. 2011 Apr; 7(2):241-50, ix.
Score: 0.085
-
Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
Score: 0.072
-
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. Am Heart J. 2007 Jun; 153(6):951-9.
Score: 0.065
-
Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm. 2017 03; 14(3):367-375.
Score: 0.031
-
Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm. 2016 05; 13(5):1066-1074.
Score: 0.029
-
Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. J Cardiovasc Electrophysiol. 2010 Sep; 21(9):1009-14.
Score: 0.020